Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ORIC PharmaceuticalsFRA:4TZ -1.88%34 EV-to-EBIT is -7.21 as of Aug. 25, 2026. GuruFocus rates FRA:4TZ with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 376 Biotechnology companies, ORIC Pharmaceuticals ranks worse than 265957.18% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ORIC Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was €687.56 Mil.
ORIC Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-134.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORIC Pharmaceuticals EV-to-EBIT Related Terms
ORIC Pharmaceuticals EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for ORIC Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4TZ vs ARDX, IMTX, TRAX: EV-to-EBIT Comparison
For the Biotechnology subindustry, ORIC Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ORIC Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ORIC Pharmaceuticals's EV-to-EBIT falls into.
ORIC Pharmaceuticals's current Enterprise Value is €968.78 Mil.
ORIC Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-134.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORIC Pharmaceuticals (FRA:4TZ) has a EV-to-EBIT of -7.21 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ORIC Pharmaceuticals and its competitors. According to the industry distribution chart, ORIC Pharmaceuticals ranks #999999 out of 376 companies in the Biotechnology industry.
Is ORIC Pharmaceuticals' EV-to-EBIT too high?
ORIC Pharmaceuticals' current EV-to-EBIT is -7.21. Based on the distribution chart, ORIC Pharmaceuticals ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ORIC Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does ORIC Pharmaceuticals' EV-to-EBIT compare to ARDX and IMTX?
According to the Biotechnology industry distribution chart, ORIC Pharmaceuticals ranks #999999 out of 376 companies for EV-to-EBIT. This places ORIC Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 16.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.28, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ORIC Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ORIC Pharmaceuticals's current EV-to-EBIT is -7.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ORIC Pharmaceuticals stock overvalued right now?
ORIC Pharmaceuticals (FRA:4TZ) has a current EV-to-EBIT of -7.21. The current EV-to-EBIT is -7.21. ORIC Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ORIC Pharmaceuticals (FRA:4TZ), the current EV-to-EBIT is -7.21 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
34GF Score
Get the complete analysis for FRA:4TZ
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4TZ has been successfully added to your 
